相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials
Boris Boell et al.
BLOOD (2016)
Variation in the HFE gene is associated with the development of bleomycin-induced pulmonary toxicity in testicular cancer patients
Gabriela G. F. van der Schoot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma
Peter Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis
James D. Williamson et al.
EXPERIMENTAL LUNG RESEARCH (2015)
Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity
Adam Jona et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Revisiting bleomycin from pathophysiology to safe clinical use
Marios Froudarakis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study
Leonard A. Minuk et al.
LEUKEMIA & LYMPHOMA (2012)
Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma
Joanne Ngeow et al.
ANNALS OF HEMATOLOGY (2011)
Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma
Amanda Wedgwood et al.
CLINICAL LYMPHOMA & MYELOMA (2007)
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis
Andrew M. Evens et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
Anas Younes et al.
EUROPEAN JOURNAL OF CANCER (2006)
Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma
WG Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients
J Nuver et al.
PHARMACOGENETICS AND GENOMICS (2005)
Gender-based differences in bleomycin-induced pulmonary fibrosis
M Gharaee-Kermani et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
How important is bleomycin in the adriamycin plus bleomycin plus vinblastine plus dacarbazine regimen?
GP Canellos et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Involvement of mast cell chymase in bleomycin-induced pulmonary fibrosis in mice
Y Tomimori et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2003)
Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis
E Azoulay et al.
CRITICAL CARE MEDICINE (2003)
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial
DB Duggan et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice
CK Haston et al.
HUMAN MOLECULAR GENETICS (2002)
A pivotal role of cytosolic phospholipase A2 in bleomycin-induced pulmonary fibrosis
T Nagase et al.
NATURE MEDICINE (2002)
Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene
J Libura et al.
EUROPEAN RESPIRATORY JOURNAL (2002)
Secondary prophylactic C-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD
A Rueda et al.
LEUKEMIA & LYMPHOMA (2001)
分享论文
